CStone Pharma (2616 HK): Placement to Fund R&D; Sugemalimab Changes Fortune For Now, What Lies Next?
​CStone Pharmaceuticals announces placement of 100M shares at HK$4.72/share for funding R&D. Attractive discount and long-term prospect of the...
445 Views
ECM Weekly (16 June 2025) - Haitian, Sanhua, Kitazato, Primo, Kioxia, Xtalpi, Horizon, Keymed, Wuxi
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
655 Views
HK Connect Flows Weekly (Jun 13th): BYD, Meituan, CCB, Innovent Biologics, Petrochina, Tencent
We analyzed the Hong Kong Connect Scheme for last week and highlighted flows for BYD, Meituan, CCB, Innovent Biologics, Petrochina, Tencent,...
929 Views
Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...
799 Views
Everest Medicine Placement: Another Sell-Down by CBC, Some Caution Warranted
Everest Medicine aims to raise around US$150m in a secondary sell-down of shares conducted by CBC Group. In this note, we comment on the deal...
808 Views